Last reviewed · How we verify
NCT05606588: PrepAIR
Preventing Sensory and Motor Dysfunctions in Children Receiving Neurotoxic Chemotherapy
NA trial testing Playful sensorimotor training in Chemotherapy-induced Peripheral Neuropathy in 131 participants. Status unknown.
31 March 2025
Quick facts
| Lead sponsor | University of Basel |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 131 |
| Start date | 1 December 2022 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2026 |
| Sites | 2 locations across Switzerland |
Drugs / interventions tested
- Playful sensorimotor training
Conditions studied
- Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
- Pediatric Cancer — all drugs for Pediatric Cancer →
Sponsor
University of Basel
Who can join
Adults 6 to 18, any sex, with Chemotherapy-induced Peripheral Neuropathy or Pediatric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators would like to conduct a prospective, multicenter, two-armed trial (RCT with follow-up). Patients will be recruited from 7 centers (CH/D). All patients (and their guardians) scheduled to receive chemotherapy containing either a platinum derivate or vinca-alkaloid, will be asked to participate. Willing patients will then be randomized either into an intervention group or a control group. Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for the duration of their medical therapy, in addition to usual care, while the control group receives treatment as usual. The CG will be given the opportunity to participate in the intervention after therapy. Data will be assessed at 3-4 time points: Prior to chemotherapy (baseline T0), after 12 weeks (T1), after completion of therapy for children that are treated \>3 months (Tp) and after 12 months follow-up (T3). Additionally, status of Chemotherapy-induced peripheral neuropathy (CIPN) reported symptoms will be monitored twice in-between (6 weeks). The investigators hypothesize that less children in the intervention group will develop symptoms of CIPN (TNS score) with its debilitating side-effects. Furthermore, children in the intervention group will be able to maintain relevant motor and sensory functions and their associated physical functions which will enable them to receive their planned medical therapy but also to stay on the age-appropriate motor development level, improve their quality life and enhance social reintegration after therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05606588
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy
Currently open trials in the same condition.
- NCT07177820 — VGAIT for Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
- NCT07072468 — Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) · Phase 2 · recruiting
- NCT06389721 — Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy · recruiting
- NCT06405542 — Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) · Phase 1 · active not recruiting
- NCT06162403 — Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longi · NA · recruiting
Other University of Basel trials
Trials by the same sponsor.
- NCT07160660 — Patients' Satisfaction and Clinical Investigation of Removable Partial Denture Anchorage With Extracoronal Adhesive Atta · enrolling by invitation
- NCT06975020 — Pilot-Study for the Comparison of Biomarkers Between Regular Cannabis Users and Non-Users · NA · recruiting
- NCT06848725 — Testing the Implementation of a Toolbox to Optimize Data Collection and Data Quality of the National Medical Quality Ind · NA · completed
- NCT06473051 — Sustainable Improvement of INTERprofessional Care for Better Resident Outcomes · NA · active not recruiting
- NCT06063135 — Effects of Physical Exercise Timing On Strength and Cardiometabolic Health · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05606588 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Basel
- Last refreshed: 4 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05606588.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing